Form 4: Regeneron VP Controller Jason Pitofsky Executes Stock Option and Sells Shares

Jason Pitofsky, VP Controller at Regeneron Pharmaceuticals, exercised stock options and sold shares on August 7, 2024.

Summary

• On August 7, 2024, Jason Pitofsky, VP Controller at Regeneron Pharmaceuticals, exercised a non-qualified stock option to acquire 487 shares of common stock at a price of $372.46.
• Simultaneously, Pitofsky sold 487 shares of Regeneron common stock at a price of $1,070 per share.
• Following these transactions, Pitofsky directly owns 4,204 shares of Regeneron common stock and indirectly owns 10 shares through a 401(k) plan.
• He also continues to hold options to purchase Regeneron stock.
• The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction disclosure. The exercise and sale don't necessarily indicate a positive or negative outlook on the company's future.

Positives

• The exercise of stock options and subsequent sale of shares indicates Pitofsky's belief in the company's long-term value, as he initially invested in the options.
• The sale at $1,070 per share provided a significant profit compared to the exercise price of $372.46.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It is common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The sale of shares could have a minor, temporary impact on the stock price.

Key Dates